The CRISPR/dCas9-VP64 activation system has been employed to demonstrate that METTL3 expression significantly promotes HCC growth both in vitro and in vivo, thereby facilitating a deeper understanding of the mechanisms underlying epigenetic alterations in liver carcinogenesis (54). The gene discussed is METTL3; the disease is hepatocellular carcinoma.